Dilaudid
Prostate Neoplasm
University of AlbertaN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Prostate Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Nuvation Bio Inc. | Phase 3 | BB |
Benadryl Merck Sharp & Dohme LLC | Phase 3 | B |
Rf-Psa National Cancer Institute (NCI) | Phase 2 | B |
Rv-Psa National Cancer Institute (NCI) | Phase 2 | B |
Rv-B7.1 National Cancer Institute (NCI) | Phase 2 | B |
View all 26 →
Same molecule, other indications
Dilaudid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →